George Abraham to Middle Aged
This is a "connection" page, showing publications George Abraham has written about Middle Aged.
Connection Strength
0.178
-
Mishra A, George AA, Sahu KK, Lal A, Abraham G. Tuberculosis and COVID-19 Co-infection: An Updated Review. Acta Biomed. 2020 11 10; 92(1):e2021025.
Score: 0.052
-
Lal A, Abraham GM. Utility of CD4 Cell Count and Viral Load Assay in Hospitalized Patients with Known HIV Infection: High Value Care Exercise. Infect Disord Drug Targets. 2020; 20(4):486-490.
Score: 0.049
-
Shanmugavel Geetha H, Teo YX, Ravichandran S, Perkit NR, Gogtay M, Lal A, Abraham GM, Trivedi N. Use of Sodium-glucose cotransporter 2 (SGLT 2) inhibitor is associated with reduced emergency room visits and hospitalizations in patients with Chronic obstructive pulmonary disease (COPD) and type 2 Diabetes Mellitus. Respir Med. 2024 Nov-Dec; 234:107819.
Score: 0.017
-
Ziegler CGK, Owings AH, Galeas-Pena M, Kazer SW, Miao VN, Navia AW, Tang Y, Bromley JD, Lotfy P, Sloan M, Laird H, Williams HB, George M, Drake RS, Pride Y, Abraham GE, Senitko M, Robinson TO, Diamond G, Lionakis MS, Shalek AK, Ordovas-Montanes J, Horwitz BH, Glover SC. An enhanced IL17 and muted type I interferon nasal epithelial cell state characterizes severe COVID-19 with fungal coinfection. Microbiol Spectr. 2024 Jun 04; 12(6):e0351623.
Score: 0.017
-
Liu JJ, Sloan ME, Owings AH, Figgins E, Gauthier J, Gharaibeh R, Robinson T, Williams H, Sindel CB, Backus F, Ayyalasomayajula K, Parker A, Senitko M, Abraham GE, Claggett B, Horwitz BH, Jobin C, Adelman RM, Diamond G, Glover SC. Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor Therapy. Am J Gastroenterol. 2021 08 01; 116(8):1638-1645.
Score: 0.014
-
Ziegler CGK, Miao VN, Owings AH, Navia AW, Tang Y, Bromley JD, Lotfy P, Sloan M, Laird H, Williams HB, George M, Drake RS, Christian T, Parker A, Sindel CB, Burger MW, Pride Y, Hasan M, Abraham GE, Senitko M, Robinson TO, Shalek AK, Glover SC, Horwitz BH, Ordovas-Montanes J. Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19. Cell. 2021 09 02; 184(18):4713-4733.e22.
Score: 0.014
-
Sterling RK, Kuo A, Rustgi VK, Sulkowski MS, Stewart TG, Fenkel JM, El-Genaidi H, Mah'moud MA, Abraham GM, Stewart PW, Akushevich L, Nelson DR, Fried MW, Di Bisceglie AM. Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. Aliment Pharmacol Ther. 2015 Apr; 41(7):671-85.
Score: 0.009
-
Chhabra L, Abraham GM, McGillicuddy GT. A nail in the head. Lancet. 2014 Feb 01; 383(9915):e10.
Score: 0.008